December 4, 2024 08:00 AM Eastern Daylight Time
BOULDER, Colo.-- Mosaic Biosciences, a drug discovery organization providing comprehensive protein and antibody therapeutics discovery services, today announced its participation in the inaugural AIntibody Challenge. This initiative aims to evaluate the potential of artificial intelligence and machine learning (AI/ML) to accelerate and innovate antibody discovery in ways not previously achieved with conventional methods.
The AIntibody Challenge seeks to rigorously test AI-driven antibody design and in silico predictions against experimentally validated datasets. Focusing on antibodies targeting the RBD (receptor-binding domain) of SARS-CoV-2, the challenge presents an ideal case study to see how AI-driven models perform with available epitope and affinity data. Mosaic’s role in this initiative will be to evaluate the developability of the designed antibodies, helping ensure they meet critical criteria for stability and manufacturability. A call for entries in the challenge was published in Erasmus, M. F., et al. (2024). "AIntibody: an experimentally validated in silico antibody discovery design challenge." Nature Biotechnology.
“AI’s potential to transform antibody discovery is both exciting and complex,” said Christilyn Graff, SVP and Head of Research at Mosaic Biosciences. “Our participation in the AIntibody Challenge provides a unique opportunity to assess the practical impact of AI in this space. At Mosaic, we’re committed to advancing drug discovery by exploring new methodologies and partnerships that accelerate therapeutic innovation.”
In addition to Mosaic, the AIntibody Series includes support from a consortium of biopharma service leaders, including Specifica, who is administering the challenge; Azenta Life Sciences, who will generate the antibodies; Carterra and Sapidyne Instruments, who will measure affinities; and Bio-Techne, who will provide target proteins. This collective effort combines scientific rigor with innovative technology to assess whether AI can effectively generate high-quality antibodies without the need for traditional experimental validation.
Mosaic Biosciences is pioneering a transformative model for drug discovery, offering biotech, biopharma, and academic institutions a fully integrated platform for therapeutic discovery, characterization, and optimization, specializing in protein therapeutics. Mosaic’s approach seamlessly incorporates essential screening, such as developability assessment and advanced cell-based assays, into the discovery process, ensuring that potential therapeutics are evaluated for their practical application from the outset. Mosaic’s partners also benefit from rapid evaluations of animal pharmacokinetic and pharmacodynamic studies, allowing for swift decision-making. With access to cutting-edge proprietary tools and data-driven methodologies, Mosaic’s nimble, multidisciplinary team of experienced scientists collaborates closely with partners to deliver innovative solutions to modern drug discovery. United by a shared commitment to advancing human health, Mosaic empowers partners to achieve therapeutic breakthroughs efficiently and effectively.
For more information on Mosaic Biosciences and its work with the AIntibody Challenge, please contact:
Tracey Mullen
[email protected]